• Media type: E-Article
  • Title: Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit
  • Contributor: Salvagno, Gian Luca; Gianfilippi, Gianluca; Pighi, Laura; De Nitto, Simone; Henry, Brandon M.; Lippi, Giuseppe
  • imprint: Walter de Gruyter GmbH, 2021
  • Published in: Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
  • Language: English
  • DOI: 10.1515/almed-2021-0041
  • ISSN: 2628-491X
  • Keywords: Medical Laboratory Technology ; Education ; Medicine (miscellaneous)
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:sec id="j_almed-2021-0041_abs_001"> <jats:title>Objectives</jats:title> <jats:p>Since commercial SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antigen rapid detection tests (Ag-RDTs) display broad diagnostic efficiency, this study aimed to evaluate the clinical performance of Fluorecare SARS-CoV-2 Spike Protein Test Kit in a real-life scenario.</jats:p> </jats:sec> <jats:sec id="j_almed-2021-0041_abs_002"> <jats:title>Methods</jats:title> <jats:p>The study population consisted of a series of patients undergoing SARS-Cov-2 diagnostic testing at Pederzoli Hospital of Peschiera del Garda (Verona, Italy). A nasopharyngeal swab was collected upon hospital admission and assayed with molecular (Altona Diagnostics RealStar<jats:sup>®</jats:sup> SARSCoV-2 RT-PCR Kit) and antigen (Fluorecare SARS-CoV-2 Spike Protein Test Kit) tests.</jats:p> </jats:sec> <jats:sec id="j_almed-2021-0041_abs_003"> <jats:title>Results</jats:title> <jats:p>The study population consisted of 354 patients (mean age, 47 ± 20 years; 195 women, 55.1%), 223 (65.8%) positive at molecular testing. A significant correlation was found between Fluorecare SARS-CoV-2 Spike Protein Test Kit and Altona (both <jats:italic>S</jats:italic> and <jats:italic>E</jats:italic> genes: r=−0.75; p&lt;0.001). The cumulative area under the curve in all nasopharyngeal samples was 0.68. At ≥1.0 S/CO manufacturer’s cut-off, the sensitivity, specificity, negative and positive predictive values were 27.5, 99.2, 41.5 and 98.5%, respectively. Considerable improvement of sensitivity was observed as Ct values decreased, becoming 66.7% in samples with mean Ct values &lt;30, 90.5% in those with mean Ct values &lt;25, up to 100% in those with mean Ct values &lt;20.</jats:p> </jats:sec> <jats:sec id="j_almed-2021-0041_abs_004"> <jats:title>Conclusions</jats:title> <jats:p>The modest sensitivity and negative predictive value of Fluorecare SARS-CoV-2 Spike Protein Test Kit makes unadvisable to use this assay as surrogate of molecular testing for definitively diagnosing SARS-CoV-2 infection, though its suitable sensitivity at high viral load could make it a reliable screening test for patients with higher infective potential.</jats:p> </jats:sec>
  • Access State: Open Access